Boston Scientific stock faces negative outlook as leverage risk rises

Published on 11/10/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock faces a tougher credit backdrop after S&P Global Ratings cut its outlook to negative. The A- rating remains affirmed.

Credit risks meet portfolio expansion

S&P Global Ratings affirmed Boston Scientific's A- ratings while revising the outlook to negative.
WATCHMAN and electrophysiology face commercial headwinds, while the Penumbra acquisition is expected to increase leverage.
Boston Scientific is targeting cost savings as it works to restore growth and reduce leverage after the transaction.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific faces a more demanding credit backdrop after S&P Global Ratings revised its outlook to negative from stable on Friday, November 6, 2026. The agency affirmed the company's A- issuer and senior unsecured debt ratings, while keeping its A-2 short-term rating unchanged. The assessment was published by S&P Global Ratings.

The rating agency linked the negative outlook to continued pressure in Boston Scientific's WATCHMAN and electrophysiology franchises. It expects revenue growth of 4.4% in 2026 and 9% in 2027, well below the company's mid- to high-teens growth rates in 2024 and 2025. S&P said the slowdown followed weaker-than-expected third-quarter results and another reduction in the company's 2026 guidance.

Key franchises face competition

WATCHMAN accounts for 10% of Boston Scientific's revenue, according to S&P. Procedures for left atrial appendage closure have slowed after clinical-trial data earlier in 2026 increased uncertainty among physicians. The agency also expects competition in that market to intensify next year.

The electrophysiology franchise contributes 16% of sales and includes the FARAPULSE platform. S&P said competition from Johnson & Johnson, Medtronic and Abbott is weighing on the business, even though the broader electrophysiology market continues to grow. Restoring market share and returning the franchise to low- to mid-single-digit growth are central conditions in the agency's path back to a stable outlook.

Penumbra adds balance-sheet pressure

Boston Scientific's planned acquisition of Penumbra for 14.5 billion US dollars is expected to close in early 2027. S&P expects adjusted leverage to rise above 3.6 times at closing, compared with its 2.5-times downside trigger, and to remain elevated for the following two years as the company integrates the deal.

The transaction also offers a growth opportunity. Penumbra generated roughly 1.4 billion US dollars of revenue in 2025, according to S&P, and operates in neurovascular and cardiovascular therapies. The agency views the portfolio as complementary and expects Boston Scientific's commercial reach to support the acquired products.

Boston Scientific has announced a restructuring program seeking 500 million US dollars in savings through 2029. S&P expects management to limit additional acquisitions and share repurchases while it integrates Penumbra and reduces leverage. A return to a stable outlook would require stronger performance from WATCHMAN and electrophysiology, mid-single-digit growth in other core franchises and leverage below 2.5 times.

Stock quote and investor focus

Boston Scientific stock traded at 39.40 euros on Lang & Schwarz at 13:09 CET on Tuesday, November 10, 2026. The credit assessment puts execution, market-share stabilization and the financing of the Penumbra transaction at the center of the investment case. The diversified cardiovascular and MedSurg portfolio remains a counterweight to the weakness in the two pressured franchises, but the path to lower leverage depends on renewed operating growth and disciplined capital allocation.